Revenue Breakdown
Composition ()
No data
Revenue Streams
Ligand Pharmaceuticals Inc (LGND) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Kyprolis, accounting for 18.5% of total sales, equivalent to $8.80M. Other significant revenue streams include Captisol and Filspari. Understanding this composition is critical for investors evaluating how LGND navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Ligand Pharmaceuticals Inc maintains a gross margin of 89.70%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 0.89%, while the net margin is 101.57%. These profitability ratios, combined with a Return on Equity (ROE) of 5.42%, provide a clear picture of how effectively LGND converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, LGND competes directly with industry leaders such as LQDA and CORT. With a market capitalization of $3.75B, it holds a significant position in the sector. When comparing efficiency, LGND's gross margin of 89.70% stands against LQDA's 94.16% and CORT's 97.79%. Such benchmarking helps identify whether Ligand Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
